Free-text search
Articles per year:
Content Types
-
Implantica secures FDA approval: “Culmination of many years of development”
Swedish-founded Implantica has received Premarket Approval (PMA) from the FDA for RefluxStop, its implant-based treatment for acid reflux.
-
Lilly launches taRNA vaccine partnership
Pharma giant Eli Lilly has entered into a collaboration with the Boston‑based biotech company Amplitude Therapeutics to develop taRNA‑based vaccine candidates against infectious diseases.
-
Isotope deal boosts Uppsala radiotherapy company
Uppsala‑based Akiram Therapeutics has signed an agreement with Germany’s ITM for the supply of lutetium‑177 to support the continued development of the company’s radiopharmaceutical therapy AKIR001.
-
Melanoma data sends Moderna shares skyrocketing
A vaccine candidate from Moderna and Merck & Co almost halved the rate of skin cancer recurrence in a late-stage trial, the two companies report. The announcement sent Moderna’s share price soaring by more than 170 per cent.
-
Coloplast delays introduction of new incontinence system
Originally scheduled for release within the financial year ending in september this year, Coloplast now expects the FDA clearence of its Intibia system no earlier than october next year.
-
“We develop vaccines no one else is developing”
Vaccines delivered via patches rather than injections. Future solutions could fundamentally reshape global health. Meet the man leading efforts to distribute vaccines where the need is greatest.
-
CEO change at Bico – ”The timing is right”
Bioconvergence company Bico Group is promoting its Chief Commercial Officer, Anders Fogelberg, to the CEO position, while current CEO and President Maria Forss is stepping down.
-
BioArctic steps into cancer research with new collaboration
BioArctic has entered a research collaboration with the Swedish‑Japanese company Mesenkia Therapeutics, marking the company’s first step into the oncology field.
-
New FDA setback for Xspray – stock plunges
The Swedish research company Xspray Pharma has received yet another negative decision from the U.S. Food and Drug Administration (FDA), linked to the company’s Italian third‑party manufacturer.
-
Trump expected to pick Heidi Overton to lead the FDA
Donald Trump is expected to nominate Heidi Overton as the new commissioner of the US Food and Drug Administration (FDA), according to several international media outlets.
-
LEO Pharma acquires dermatology drug for 435 million USD
LEO Pharma strengthens its dermatology portfolio by acquiring the late-stage drug candidate dersimelagon.
-
Pila Pharma cleared to begin obesity trial
Swedish–Danish Pila Pharma has received approval from the European Medicines Agency (EMA) to begin a clinical trial of the company’s drug candidate for obesity.
-
Life sciences fuel Greater Copenhagen's economic growth
The expansion of the life sciences sector on the Danish side of the Øresund is a key reason why the Danish-Swedish Greater Copenhagen region has emerged as one of Northern Europe's strongest growth hubs.
-
Sanofi cuts 229 jobs following $9.1bn acquisition
A new round of job cuts is hitting the US biotech hub of Massachusetts. Sanofi is cutting 229 positions and closing former Blueprint offices, while Merck KGaA is also reducing headcount in its US R&D operations.
-
Evaxion drops solid tumour vaccine to advance new glioblastoma program
Danish biotech company Evaxion is discontinuing a vaccine candidate for solid tumors and redirecting resources to a program specifically aimed at brain cancer.
-
CAR‑T developer Elicera appoints new CEO
Swedish CAR‑T developer Elicera has appointed Johan Liwing as its new CEO, succeeding Jamal El‑Mosleh, who is stepping down.
-
Potions, Placebos and Perilous Practices – Macabre Mistakes in the History of Medicine
Tobacco for cancer, heroin for coughs, mercury for teething babies. Humanity’s path towards today’s evidence‑based medicine has been lined with strange misjudgements, outright quackery and “cures” that often caused more harm than good.
-
“Ozempic babies” – myth or reality?
Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.
-
Hacker group claims Chinese bid for stolen Novo data
Earlier this year, Novo Nordisk was hit by a high‑profile data breach in which a large amount of sensitive information was stolen. Now a hacker group claims that it was offered millions of dollars for the stolen data from a Chinese company – but instead published the information openly on the internet.
-
Lantheus challenges Eli Lilly with FDA-approved Alzheimer’s tracer
Eli Lilly has until now had the US market for tau PET imaging in Alzheimer’s disease to itself. The pharmaceutical giant is now facing competition after the FDA approved radiopharmaceutical company Lantheus Holdings’s Tauklarify.
-
AstraZeneca scraps late‑stage study – and reports dual successes in lung cancer
AstraZeneca is discontinuing a global Phase III trial that has been evaluating the antibody volrustimig for non‑small cell lung cancer after the chances of success were deemed low. At the same time, the company is reporting promising data for two other lung‑cancer candidates.
-
Life Science Nordic launches – bringing Nordic life science news under one roof
Welcome to Life Science Nordic – your source for the news and insights shaping the Nordic life science and medtech industries. We provide independent, in-depth journalism covering developments across the Nordic market.
-
Hansa chair: “Too many boards spend far too much time looking inwards”
Following a change of chief executive and a sharper strategic focus, Hansa Biopharma is entering a decisive phase in the US market. As the company prepares for what comes next, chair Peter Nicklin is clear about his own role: to lead the board, but never dominate it.
-
Gold Rush in Oral Peptides: “Everybody Wants In”
After Ozempic, pharmaceutical companies are racing toward the next big revolution: peptides that can be swallowed as easily as they can be injected. Cyprumed is building the technology to get them there.
BREAKING